Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026

Tenaya Therapeutics, Inc.

2025-Q1 EPS reported -$0.24

Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
Cash, equivalents and investments $88.2M at March 31; March public offering netted $48.8M, extending runway into H2 2026.
TN-201 low-dose cohort showed improved NYHA class in all 3 patients and hypertrophy improvement in 2 of 3; Cohort 2 enrollment on track.
TN-401 RIDGE-1 Phase 1b enrollment on track for H1 2025; initial data expected H2 2025.
Restructuring with workforce reduction estimated at $1.6-$2.7M charges to extend cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.